1. The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices. All therapy adjustments should be based on measurements obtained from standard blood glucose monitoring devices. All therapy adjustments should be based on measurements obtained using a home blood glucose meter and not on values provided by the system.
2. Guardian^™ Connect system SSED, page 19, Table 5. 90.5% Glucose Correct Detection Rate without Predictive Alerts at both 15 and 30 minutes when worn on the abdomen.
3. Guardian^™ Connect system SSED, page 19, Table 5. 98.5% Glucose Correct Detection Rate based on Predictive Alerts at 30 minutes when worn on the abdomen.
† Smart CGM predicts future high and low sensor glucose events up to 60 minutes in advance.
‡ Android is a trademark of Google LLC.
* Alerts must be set to receive predictive alerts.
** Data may not appear or be delayed in certain instances, including when there is no internet connection.
§ The patient testimonials above relates an account of an individual’s response to treatment. The account is genuine, typical and documented. However, this patient’s response does not provide any indication, guide, warranty or guarantee as to the response other people may have to the treatment. The response other individuals have to the treatment could be different. Responses to the treatment can and do vary. Not every response is the same. Please talk to your doctor about your condition and the risks and benefits of these technologies.

Important Safety Information: Guardian^™ Connect CGM System
The Guardian^™ Connect system requires a prescription and is indicated for continuous or periodic monitoring of glucose levels in the interstitial fluid under the skin, in patients (14 to 75 years of age) with diabetes mellitus. The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices, and is not recommended for people who are unwilling or unable to perform a minimum of two meter blood glucose tests per day, or for people who are unable or unwilling to maintain contact with their healthcare professional. The system requires a functioning mobile electronic device with correct settings. If the mobile device is not set up or used correctly, you may not receive sensor glucose information or alerts. For complete details of the system and its components, including warnings, contraindications, and precautions, please consult the user guide at http://www.medtronicdiabetes.com/support/download-library/user-guides and important safety information.

Important Safety Information: CareLink^™ Software
The CareLink^™ software is intended for use as a tool to help manage diabetes. The purpose of the software is to take information transmitted from insulin pumps, glucose meters and continuous glucose monitoring systems, and turn it into CareLink^™ reports. The reports provide information that can be used to identify trends and track daily activities—such as carbohydrates consumed, meal times, insulin delivery, and glucose readings. NOTE: CareLink^™ report data is intended for use as an adjunct in the management of diabetes only and NOT intended to be relied upon by itself. Patients should consult their healthcare providers familiar with the management of diabetes prior to making changes in treatment. For more details, please consult important safety information. and the appropriate CareLink^™ User Guide at http://www.medtronicdiabetes.com/support/download-library/user-guides.

Important Safety Information: i-Port Advance^™ Injection Port
i-Port Advance™ injection port is indicated for patients who administer or receive multiple daily subcutaneous injections of physician prescribed medications, including insulin. The device may remain in place for up to 72 hours to accommodate multiple injections without the discomfort of additional needle sticks. i-Port Advance™ injection port may be used on a wide range of patients, including adults and children. Prescription required. For more, please see http://www.medtronicdiabetes.com/important-safety-information.

Important Safety Information: InPen^™
The InPen^™ is a home- use reusable pen injector for single- patient use by people with diabetes under the supervision of an adult caregiver, or by a patient age 7 and older for the self- injection of a desired dose of insulin and for calculating an insulin dose or carbohydrate intake based on user entered data. A healthcare professional must assist in dosage programming of the device prior to use, based on various patient- specific criteria and targets. The InPen^™ requires a prescription. For additional product and safety information, please consult the Instructions for Use and bit.ly/InPenRisks.